#ZIIHERA #Ireland #Dublin #Jazz Pharmaceuticals #Zanidatamab

Jazz Pharmaceuticals Presents Promising Data at ASCO 2025

On June 2, 2025, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) took center stage at the American Society of Clinical Oncology (ASCO) Annual Meeting with a significant announcement. The company revealed long-term survival data from their Phase 2 study of Ziihera® (zanidatamab-hrii), a dual HER2-targeted bispecific antibody. This drug has been evaluated in combination with chemotherapy for patients with first-line HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA).

The trial's findings are notably critical, as they include the first report detailing median overall survival (OS). Out of a cohort of 41 patients with verified HER2-positive tumors, treatments combining Ziihera with a physician's selected chemotherapy achieved an average OS of 36.5 months, alongside a respectable median progression-free survival (PFS) of 15.2 months. The median duration of follow-up reached an impressive four years, further solidifying the relevance of these findings.

The results generated from the phase 2 study have been consistently favorable, and this latest data was simultaneously published in The Lancet Oncology. Encouragingly, among the 46 patients examined overall, the median OS remained at 36.5 months, with the longest recorded survival extending up to a remarkable 57.9 months. This highlights the potential of Ziihera in a therapeutic area with significant unmet needs, given the prognosis of patients suffering from gastroesophageal adenocarcinoma is typically poor, with existing treatment regimens yielding median survival rates between 15 and 20 months.

Dr. Elena Elimova from Princess Margaret Cancer Centre expressed the urgency of new treatments, stating, "Gastroesophageal adenocarcinoma remains a highly aggressive cancer with a poor prognosis... The long-term survival outcomes presented today at ASCO demonstrate the sustained antitumor activity achieved with zanidatamab plus chemotherapy over four years of follow-up. These results are especially encouraging given the high unmet need for better first-line treatment options for this patient population."

In addition to the significant survival rates, the ongoing study recorded low levels of treatment discontinuation due to side effects, and there were no new safety signals noted. The safety profile demonstrated manageable incidences of Grade 3-4 treatment-related adverse events, the most common being diarrhea (39%) and hypokalemia (22%). Strategies such as proactive administration of antidiarrheal prophylaxis resulted in noticeable reductions in the incidence of severe diarrhea among newer study participants.

Jazz Pharmaceuticals remains optimistic about the future of Ziihera, with Rob Iannone, the Executive Vice President of Global R&D, commenting on the significance of the results. He emphasized the strength of Ziihera as a potential change maker in treatment pathways for HER2-positive mGEA. The impending Phase 3 HERIZON-GEA-01 trial aims to further investigate the efficacy of Ziihera combined with standard care chemotherapy and a PD-1 agent, with top-line results expected to unfold later in 2025.

The Significance of Ziihera®

Ziihera (zanidatamab-hrii) stands out for its unique bispecific focus on HER2, binding to two extracellular HER2 sites. This dual targeting mechanism leads to enhanced internalization of HER2, effectively reducing its expression on tumor cells. The studies conducted thus far have recognized Ziihera's capacity to incite both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC), contributing substantially to observed tumor inhibition and cell demise in both in vitro and in vivo scenarios.

Jazz Pharmaceuticals champions Ziihera as part of its mission to develop transformative therapies for patients with serious health conditions. This biopharma company, headquartered in Dublin, Ireland, continues to innovate in oncology and other therapeutic areas, striving to improve the lives of patients with currently limited treatment options. With an expansive pipeline of research under development, the outlook for patients requires close monitoring as these therapies evolve.

Jazz's commitment to advancing Ziihera across various cancer types aligns with its broader objective to deliver groundbreaking solutions for individuals facing dire medical patters. The continued pursuit for innovative intervention strategies against aggressive cancers underlines a promising horizon for patients diagnosed with metastatic gastroesophageal adenocarcinoma and beyond.